- adalimumab was initiated for a refractory psoriasis but the peripheral neuropathy became unbearable leading to double the duloxetine’s dosage while she had a long-standing treatment by duloxetine and pregabalin, - authors did not suggest any interaction’s mechanism but it could be possible that the decrease of TNF-α by adalimumab led to a lift of the inhibition of CYPs, - no apparent interaction with pregabalin, which is eliminate by renal way. This evidence concerns the gene TNF and peripheral neuropathy.